GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ProSomnus Inc (OTCPK:OSAPQ) » Definitions » Change In Working Capital

ProSomnus (ProSomnus) Change In Working Capital : $0.11 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is ProSomnus Change In Working Capital?

ProSomnus's change in working capital for the quarter that ended in Mar. 2024 was $-1.15 Mil.

ProSomnus's change in working capital for the fiscal year that ended in Dec. 2023 was $1.45 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).


ProSomnus Change In Working Capital Historical Data

The historical data trend for ProSomnus's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProSomnus Change In Working Capital Chart

ProSomnus Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Change In Working Capital
1.62 1.64 -1.49 1.45

ProSomnus Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 1.01 1.09 -0.85 -1.15

ProSomnus Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.11 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ProSomnus Change In Working Capital Related Terms

Thank you for viewing the detailed overview of ProSomnus's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


ProSomnus (ProSomnus) Business Description

Traded in Other Exchanges
N/A
Address
5675 Gibraltar Drive, Pleasanton, CA, USA, 94588
ProSomnus Inc is a medical device manufacturer. It manufacturers precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus's patented devices are more comfortable and less invasive alternative to continuous positive airway pressure therapy, and lead to more effective and patient-preferred outcomes.
Executives
Sung Kim officer: Chief Technical Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
John Steffens 10 percent owner C/O DIGITALBRIDGE GROUP, INC., 750 PARK OF COMMERCE DRIVE SUITE 210, BOCCA RATON FL 33487
Gregory P. Ho 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Brian B Dow officer: Chief Financial Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Smc Holdings Ii, Lp 10 percent owner 65 EAST 55TH STREET, 33RD FLOOR, NEW YORK NY 10022
Smc Holdings Ii G.p., Llc 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Laing Rikkers director 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Len Liptak director, officer: Chief Executive Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Mark Thomas Murphy officer: Chief Growth Officer 5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Hgp Iii, Llc 10 percent owner 3708 ASHFORD PLACE, GREENVILLE NC 27858
Steven Robert Pacelli director 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Hmc, Llc 10 percent owner 3708 ASHFORD PLACE, GREENVILLE NC 27858
Healthpointcapital, Llc 10 percent owner C/O HEALTHPOINTCAPITAL, 505 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Healthpointcapital Partners Iii Lp 10 percent owner 505 Park Avenue, 12th Floor, New York NY 10022
Leonard Hedge director 7855 BELLA MONTANIA LANE, PALO CEDRO CA 96073